We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PGEN generated $11.9M in operating cash flow while advancing redosing, pediatric and international expansion.
Precigen, Inc. (PGEN - Free Report) centered its third-quarter 2026 earnings call on accelerating adoption of PAPZIMEOS and defending its early lead in recurrent respiratory papillomatosis (RRP).
Management emphasized expanding treatment access, positive cash generation and preparations for competition, while outlining additional indications and pipeline opportunities.
Precigen Sees PAPZIMEOS Adoption Broadening
Chief commercial officer Phil Tennant said more than 500 patients had started PAPZIMEOS treatment and more than 300 had completed it. Over 600 patients were registered in the company’s support hub.
Tennant emphasized that institutions increasingly handle access and reimbursement independently, meaning hub registrations do not capture every treated patient. Patients with fewer than three surgeries in the preceding year also represent a meaningful share of uptake.
PAPZIMEOS generated $72.9 million in quarterly net revenue, up 37% sequentially. Total revenues of $74.15 million trailed the Zacks Consensus Estimate of $75.43 million, while earnings of 8 cents per share missed the 9-cent estimate.
President and CEO Helen Sabzevari highlighted the therapy’s 51% complete response rate in its pivotal study, durable responses extending up to five years and straightforward subcutaneous administration.
Sabzevari also emphasized PAPZIMEOS’ full FDA approval without a confirmatory trial requirement. The company describes its broad adult indication and existing reimbursement infrastructure as competitive advantages.
During questions about Inovio’s prospective launch, Tennant said Precigen had planned for competition from the outset. He pointed to established payer policies, physician experience and treatment-site capabilities while expressing confidence in the product’s position.
Precigen Discusses Growth Without Q4 Targets
A Citizens JMP Securities analyst asked whether third-quarter sequential growth could continue into the fourth quarter. Tennant cited favorable indicators, including additional ordering accounts, patient starts and hub activity.
A B. Riley Securities analyst pressed for monthly sales trends and October momentum. Sabzevari declined to provide month-by-month guidance, while Tennant emphasized the continued activation of sites ordering PAPZIMEOS.
The company therefore framed its near-term outlook through commercial activity rather than a numerical sales forecast. Management reiterated confidence in ongoing growth without specifying a fourth-quarter revenue target.
PGEN Links Commercial Scale to Cash Generation
The company reported $35.8 million in quarterly net income and $11.9 million in cash from operations, achieving positive quarterly cash flow ahead of the company’s prior timetable.
Cash, cash equivalents and investments totaled $51 million at quarter-end, alongside $96.5 million in trade receivables. Chief financial officer Harry Thomasian expected those receivables to be collected over the following four months.
He also cited an additional $25 million available under the debt facility and said management did not currently anticipate raising more capital. The company expects U.S. PAPZIMEOS gross margins to stabilize in the high-80% to low-90% range.
Precigen Pursues New Patient Groups and Markets
Sabzevari identified redosing, pediatric development and international expansion as the principal opportunities to extend PAPZIMEOS beyond its current adult U.S. market.
The redosing trial is enrolling patients to evaluate whether partial responders can achieve complete responses after another course. Management also intends to pursue treatment options for children with RRP.
In Europe, the marketing authorization application remains under review. Asked by an Evercore ISI analyst about commercialization strategy, Sabzevari said Precigen was assessing potential ex-U.S. partnerships while retaining the ability to execute independently.
PGEN Advances Its AdenoVerse Pipeline
Sabzevari described the FDA’s September platform technology designation for AdenoVerse as a means of leveraging existing manufacturing and preclinical knowledge across future programs.
She highlighted PRGN-2009, an investigational immunotherapy targeting HPV-associated diseases, as the next major development opportunity built on that platform.
Management plans to present new Phase 2 data in HPV-associated head and neck cancer at a forthcoming R&D Day, alongside a broader development update.
Precigen Maintains Its Commercial Priorities
Management’s message combined confidence in the existing PAPZIMEOS launch with a commitment to broader access and disciplined pipeline investment.
The next phase centers on expanding treatment adoption, navigating emerging competition and advancing additional indications without abandoning financial discipline.
PGEN Zacks Rank and Style Scores in Focus
PGEN carries a Zacks Rank #2 (Buy), indicating favorable earnings-estimate revision characteristics. Its Growth Score of B and Momentum Score of A provide stronger style signals than its Value Score of D. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Its VGM Score of C reflects a less compelling combined profile than the A or B scores highlighted in the Zacks framework. The current Zacks Rank may change as analysts revise estimates following the quarterly results.
View the Zacks #1 Rank List
Image: Bigstock
PGEN Q3 Earnings Call Highlights Launch Momentum and Competition
Key Takeaways
Precigen, Inc. (PGEN - Free Report) centered its third-quarter 2026 earnings call on accelerating adoption of PAPZIMEOS and defending its early lead in recurrent respiratory papillomatosis (RRP).
Management emphasized expanding treatment access, positive cash generation and preparations for competition, while outlining additional indications and pipeline opportunities.
Precigen Sees PAPZIMEOS Adoption Broadening
Chief commercial officer Phil Tennant said more than 500 patients had started PAPZIMEOS treatment and more than 300 had completed it. Over 600 patients were registered in the company’s support hub.
Tennant emphasized that institutions increasingly handle access and reimbursement independently, meaning hub registrations do not capture every treated patient. Patients with fewer than three surgeries in the preceding year also represent a meaningful share of uptake.
PAPZIMEOS generated $72.9 million in quarterly net revenue, up 37% sequentially. Total revenues of $74.15 million trailed the Zacks Consensus Estimate of $75.43 million, while earnings of 8 cents per share missed the 9-cent estimate.
Precigen, Inc. Price, Consensus and EPS Surprise
Precigen, Inc. price-consensus-eps-surprise-chart | Precigen, Inc. Quote
chart
PGEN Defends Its Position Ahead of Competition
President and CEO Helen Sabzevari highlighted the therapy’s 51% complete response rate in its pivotal study, durable responses extending up to five years and straightforward subcutaneous administration.
Sabzevari also emphasized PAPZIMEOS’ full FDA approval without a confirmatory trial requirement. The company describes its broad adult indication and existing reimbursement infrastructure as competitive advantages.
During questions about Inovio’s prospective launch, Tennant said Precigen had planned for competition from the outset. He pointed to established payer policies, physician experience and treatment-site capabilities while expressing confidence in the product’s position.
Precigen Discusses Growth Without Q4 Targets
A Citizens JMP Securities analyst asked whether third-quarter sequential growth could continue into the fourth quarter. Tennant cited favorable indicators, including additional ordering accounts, patient starts and hub activity.
A B. Riley Securities analyst pressed for monthly sales trends and October momentum. Sabzevari declined to provide month-by-month guidance, while Tennant emphasized the continued activation of sites ordering PAPZIMEOS.
The company therefore framed its near-term outlook through commercial activity rather than a numerical sales forecast. Management reiterated confidence in ongoing growth without specifying a fourth-quarter revenue target.
PGEN Links Commercial Scale to Cash Generation
The company reported $35.8 million in quarterly net income and $11.9 million in cash from operations, achieving positive quarterly cash flow ahead of the company’s prior timetable.
Cash, cash equivalents and investments totaled $51 million at quarter-end, alongside $96.5 million in trade receivables. Chief financial officer Harry Thomasian expected those receivables to be collected over the following four months.
He also cited an additional $25 million available under the debt facility and said management did not currently anticipate raising more capital. The company expects U.S. PAPZIMEOS gross margins to stabilize in the high-80% to low-90% range.
Precigen Pursues New Patient Groups and Markets
Sabzevari identified redosing, pediatric development and international expansion as the principal opportunities to extend PAPZIMEOS beyond its current adult U.S. market.
The redosing trial is enrolling patients to evaluate whether partial responders can achieve complete responses after another course. Management also intends to pursue treatment options for children with RRP.
In Europe, the marketing authorization application remains under review. Asked by an Evercore ISI analyst about commercialization strategy, Sabzevari said Precigen was assessing potential ex-U.S. partnerships while retaining the ability to execute independently.
PGEN Advances Its AdenoVerse Pipeline
Sabzevari described the FDA’s September platform technology designation for AdenoVerse as a means of leveraging existing manufacturing and preclinical knowledge across future programs.
She highlighted PRGN-2009, an investigational immunotherapy targeting HPV-associated diseases, as the next major development opportunity built on that platform.
Management plans to present new Phase 2 data in HPV-associated head and neck cancer at a forthcoming R&D Day, alongside a broader development update.
Precigen Maintains Its Commercial Priorities
Management’s message combined confidence in the existing PAPZIMEOS launch with a commitment to broader access and disciplined pipeline investment.
The next phase centers on expanding treatment adoption, navigating emerging competition and advancing additional indications without abandoning financial discipline.
PGEN Zacks Rank and Style Scores in Focus
PGEN carries a Zacks Rank #2 (Buy), indicating favorable earnings-estimate revision characteristics. Its Growth Score of B and Momentum Score of A provide stronger style signals than its Value Score of D. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Its VGM Score of C reflects a less compelling combined profile than the A or B scores highlighted in the Zacks framework. The current Zacks Rank may change as analysts revise estimates following the quarterly results.